Therapeutic effects of different regimens for induction therapy in elderly patients more than 50 years old with newly diagnosed acute myeloid leukaemia

Translational Cancer Research ◽

10.21037/tcr.2018.12.21 ◽

2018 ◽

Vol 7 (6) ◽

pp. 1675-1681

Author(s):

Junmei Liu ◽

Liang Zhong ◽

Juanjuan Yao ◽

Pengqiang Zhong ◽

Zhen Yuan ◽

...

Keyword(s):

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Induction Therapy ◽

Therapeutic Effects ◽

Newly Diagnosed ◽

Download Full-text

Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia

10.1186/s12885-018-5160-5 ◽

2018 ◽

Vol 18 (1) ◽

Author(s):

Jiayu Huang ◽

Huihui Zhao ◽

Ming Hong ◽

Han Zhu ◽

Yu Zhu ◽

...

Keyword(s):

Platelet Count ◽

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Prognostic Marker ◽

Induction Chemotherapy ◽

Newly Diagnosed ◽

Early Recovery ◽

Download Full-text

Low-dose combination remission induction therapy for acute myeloid leukaemia in elderly patients - a pilot study

Australian and New Zealand Journal of Medicine ◽

10.1111/j.1445-5994.1992.tb04888.x ◽

1992 ◽

Vol 22 (6) ◽

pp. 710-711 ◽

Author(s):

A. MANOHARAN

Keyword(s):

Pilot Study ◽

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Induction Therapy ◽

Low Dose ◽

Remission Induction ◽

Dose Combination ◽

Download Full-text

Low-dose combination remission induction therapy for acute myeloid leukaemia in elderly patients – a pilot study

Internal Medicine Journal ◽

10.1111/j.1445-5994.1992.tb00521.x ◽

1992 ◽

Vol 22 (6) ◽

pp. 710-711

Author(s):

A. MANOHARAN

Keyword(s):

Pilot Study ◽

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Induction Therapy ◽

Low Dose ◽

Remission Induction ◽

Dose Combination ◽

Download Full-text

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00362-9 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1691-1699 ◽

Author(s):

Christoph Röllig ◽

Hubert Serve ◽

Andreas Hüttmann ◽

Richard Noppeney ◽

Carsten Müller-Tidow ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Standard Therapy ◽

Controlled Trial ◽

Phase 2 ◽

Newly Diagnosed ◽

Multicentre Phase ◽

Randomised Controlled ◽

Download Full-text

Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?

Best Practice & Research Clinical Haematology ◽

10.1016/j.beha.2009.10.003 ◽

2009 ◽

Vol 22 (4) ◽

pp. 509-515 ◽

Author(s):

Jacob M. Rowe

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Induction Therapy ◽

Download Full-text

Elderly Patients with Acute Myeloid Leukaemia: Characteristics in Biology, Patients and Treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (ÖGHO) and the German Society for Geriatrics (DGG)

Oncology Research and Treatment ◽

10.1159/000075610 ◽

2004 ◽

Vol 27 (1) ◽

pp. 72-82 ◽

Author(s):

U. Wedding ◽

C. Bokemeyer ◽

J.G. Meran

Keyword(s):

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Working Group ◽

Geriatric Oncology ◽

German Society ◽

Treatment Recommendations ◽

Austrian Society ◽

Download Full-text

Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy

Hematological Oncology ◽

10.1002/hon.834 ◽

2008 ◽

Vol 26 (1) ◽

pp. 33-38 ◽

Author(s):

Nobuhiro Kanemura ◽

Hisashi Tsurumi ◽

Senji Kasahara ◽

Takeshi Hara ◽

Toshiki Yamada ◽

...

Keyword(s):

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Low Dose ◽

Intensive Chemotherapy ◽

Granulocyte Colony Stimulating Factor ◽

Colony Stimulating Factor ◽

Stimulating Factor ◽

Low Dose Cytarabine ◽

Download Full-text

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(13)70037-8 ◽

2013 ◽

Vol 14 (4) ◽

pp. 354-362 ◽

Author(s):

Jorge Cortes ◽

Eric Feldman ◽

Karen Yee ◽

David Rizzieri ◽

Anjali S Advani ◽

...

Keyword(s):

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Phase 2 Study ◽

Open Label Phase ◽

Dosing Regimens ◽

Download Full-text

7 + 3 idarubicin is still an effective induction therapy in acute myeloid leukaemia

Internal Medicine Journal ◽

10.1111/imj.12492 ◽

2014 ◽

Vol 44 (8) ◽

pp. 823-824 ◽

Author(s):

S. Ramanathan ◽

M. Brereton ◽

M. Rezo ◽

X. Badoux

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Induction Therapy ◽

Download Full-text

PKP-005 Prognostic impact of novel gene polymorphisms in newly diagnosed acute myeloid leukaemia adults undergoing induction chemotherapy: Abstract PKP-005 Table 1

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2015-000639.321 ◽

2015 ◽

Vol 22 (Suppl 1) ◽

pp. A133.1-A133

Author(s):

J Megías Vericat ◽

P Montesinos ◽

M Herrero ◽

F Moscardó ◽

V Bosó ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Induction Chemotherapy ◽

Gene Polymorphisms ◽

Prognostic Impact ◽

Newly Diagnosed ◽

Download Full-text